WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentPreface
Afficher le documentIntroduction
Ouvrir ce répertoire et afficher son contenuParasitic infections
Ouvrir ce répertoire et afficher son contenuInsect and arachnid bites and stings
Ouvrir ce répertoire et afficher son contenuSuperficial fungal infections
Ouvrir ce répertoire et afficher son contenuSubcutaneous fungal infections
Ouvrir ce répertoire et afficher son contenuBacterial infections
Ouvrir ce répertoire et afficher son contenuViral infections
Ouvrir ce répertoire et afficher son contenuEczematous diseases
Ouvrir ce répertoire et afficher son contenuScaling diseases
Ouvrir ce répertoire et afficher son contenuPapulosquamous diseases
Afficher le documentCutaneous reactions to drugs
Ouvrir ce répertoire et afficher son contenuPigmentary disorders
Ouvrir ce répertoire et afficher son contenuPremalignant lesions and malignant tumours
Ouvrir ce répertoire et afficher son contenuPhotodermatoses
Ouvrir ce répertoire et afficher son contenuBullous dermatoses
Afficher le documentAlopecia areata
Afficher le documentUrticaria
Ouvrir ce répertoire et afficher son contenuConditions common in children
Afficher le documentAcne vulgaris
Afficher le documentPruritus
Afficher le documentTropical ulcers
Ouvrir ce répertoire et afficher son contenuAntimicrobial drugs
Ouvrir ce répertoire et afficher son contenuAntifugal drugs
Ouvrir ce répertoire et afficher son contenuAntiseptic agents
Ouvrir ce répertoire et afficher son contenuKeratoplastic and keratolytic agents
Ouvrir ce répertoire et afficher son contenuScabicides and pediculicides
Fermer ce répertoireAnti-inflammatory and antipruritic drugs1
Afficher le documentBetamethasone
Afficher le documentCalamine lotion
Afficher le documentHydrocortisone
Afficher le documentPrednisolone
Ouvrir ce répertoire et afficher son contenuAntiallergics and drugs used in anaphylaxis
Ouvrir ce répertoire et afficher son contenuUltraviolet radiation-blocking agents (sunscreens)
Ouvrir ce répertoire et afficher son contenuMiscellaneous drugs
Ouvrir ce répertoire et afficher son contenuAnnex
Afficher le documentSelected WHO Publications of Related Interest
Afficher le documentBack cover
 

Betamethasone

Ointment or cream, 0.1% (as valerate)

General information

Betamethasone is a topical corticosteroid preparation of high potency. Its therapeutic effects result from vasoconstriction, reduction of membrane permeability, and suppression of mitotic activity and the immune response.

Clinical information

Uses

Short-term treatment of non-infectious dermatoses (including contact, atopic and seborrhoeic dermatitis, psoriasis and actinic prurigo).

Dosage and administration

Adults and children over 2 years: a thin layer of ointment should be applied to the affected area twice or three times daily. The frequency of application is gradually reduced as improvement occurs.

Contraindications

• Known hypersensitivity to corticosteroids.
• Infections of the skin.
• Age under 2 years.

Precautions

Prolonged therapy or treatment of large areas of skin should be avoided as adrenal suppression can occur.

Betamethasone should not be used on the face for more than 7 consecutive days.

If secondary infection occurs during treatment, betamethasone should be withdrawn and an appropriate antimicrobial given.

Use in pregnancy

Betamethasone should not be used in large amounts or for more than 2 weeks during pregnancy.

Adverse effects

Existing infections may be exacerbated.

Prolonged use can induce atrophy of the skin, particularly on the face and in skin-folds. This is characterized by thinning of the dermis, depigmentation, dilatation of superficial blood vessels and formation of striae.

Infants and young children are particularly susceptible to the local and systemic effects of topical corticosteroids. Prolonged use can result in hypercorticalism and suppression of the hypothalamic-pituitary-adrenal axis.

Storage

Cream and ointment should be stored in well-closed containers.

vers la section précédente
vers la section suivante
 
 
Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 1 décembre 2019